Vascular Biogenics Stock Price To Earnings To Growth
VBLTDelisted Stock | USD 0.28 0.01 3.45% |
Vascular Biogenics fundamentals help investors to digest information that contributes to Vascular Biogenics' financial success or failures. It also enables traders to predict the movement of Vascular Stock. The fundamental analysis module provides a way to measure Vascular Biogenics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vascular Biogenics stock.
Vascular |
Vascular Biogenics Company Price To Earnings To Growth Analysis
Vascular Biogenics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
CompetitionBased on the latest financial disclosure, Vascular Biogenics has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Vascular Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vascular Biogenics' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vascular Biogenics could also be used in its relative valuation, which is a method of valuing Vascular Biogenics by comparing valuation metrics of similar companies.Vascular Biogenics is currently under evaluation in price to earnings to growth category among its peers.
Vascular Fundamentals
Return On Equity | -0.6 | |||
Return On Asset | -0.29 | |||
Operating Margin | (33.89) % | |||
Current Valuation | (10.99 M) | |||
Shares Outstanding | 77.64 M | |||
Shares Owned By Insiders | 13.48 % | |||
Shares Owned By Institutions | 14.00 % | |||
Number Of Shares Shorted | 250.34 K | |||
Price To Earning | (9.32) X | |||
Price To Book | 0.35 X | |||
Price To Sales | 9.63 X | |||
Revenue | 658 K | |||
Gross Profit | 554 K | |||
EBITDA | (31.16 M) | |||
Net Income | (32.3 M) | |||
Cash And Equivalents | 34.15 M | |||
Cash Per Share | 0.49 X | |||
Total Debt | 564 K | |||
Debt To Equity | 0.05 % | |||
Current Ratio | 4.05 X | |||
Book Value Per Share | 0.27 X | |||
Cash Flow From Operations | (31.59 M) | |||
Short Ratio | 0.55 X | |||
Earnings Per Share | (0.18) X | |||
Target Price | 5.0 | |||
Beta | 0.71 | |||
Market Capitalization | 13.83 M | |||
Total Asset | 29.66 M | |||
Retained Earnings | (294.38 M) | |||
Working Capital | 15.42 M | |||
Current Asset | 38.59 M | |||
Current Liabilities | 4.16 M | |||
Z Score | -2.01 | |||
Net Asset | 29.66 M |
About Vascular Biogenics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vascular Biogenics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vascular Biogenics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vascular Biogenics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in Vascular Stock
If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |